Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Une étude de l'I-DXd en association avec l'atezolizumab avec ou sans carboplatine comme induction ou entretien de première intention chez des sujets atteints d'un cancer du poumon à petites cellules de stade étendu (IDeate-Lung03)

28 septembre 2026 mis à jour par: Daiichi Sankyo

Une étude de phase 1b/2, multicentrique et ouverte sur l'ifinatamab Deruxtecan (I-DXd), un conjugué anticorps-médicament (ADC) B7-H3, en association avec l'atezolizumab avec ou sans carboplatine comme induction ou d'entretien de première intention, en Sujets atteints d'un cancer du poumon à petites cellules de stade étendu (ES-SCLC) (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Aperçu de l'étude

Description détaillée

This study consists of two parts and two cohorts: Part A (Phase 1b; Safety Run-in) and Part B (Phase 2; Dose Optimization), Cohort 1 (I-DXd in maintenance) and Cohort 2 (I-DXd in induction + maintenance).

The primary objective of this study is to evaluate the safety and tolerability of I-DXd in combination with atezolizumab with or without carboplatin by assessing treatment-emergent adverse events (TEAEs) and other safety parameters which will inform optimal dose selection of I-DXd in the combination regimens (Dose Optimization Part B) of this study.

Type d'étude

Interventionnel

Inscription (Estimé)

123

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

      • Barcelona, Espagne, 08036
        • Recrutement
        • Hospital Clinic de Barcelona
        • Contact:
          • Principal Investigator
      • Barcelona, Espagne, 8035
        • Recrutement
        • Hospital Universitari Vall D'Hebron
        • Contact:
          • Principal Investigator
      • Girona, Espagne, 17007
        • Recrutement
        • Ico Girona - Hospital Universitari de Girona Dr Josep Trueta
        • Contact:
          • Principal Investigator
      • L'Hospitalet de Llobregat, Espagne, 08908
        • Recrutement
        • ICO l'Hospitalet - Hospital Duran i Reynals
        • Contact:
          • Principal Investigator
      • Madrid, Espagne, 28041
        • Recrutement
        • Hospital Universitario 12 de Octubre
        • Contact:
          • Principal Investigator
      • Madrid, Espagne, 28007
        • Recrutement
        • Hospital General Universitario Gregorio Marañon
        • Contact:
          • Principal Investigator
      • Madrid, Espagne, 28034
        • Recrutement
        • Hospital Universitario Ramon Y Cajal
        • Contact:
          • Principal Investigator
      • Madrid, Espagne, 28223
        • Recrutement
        • Next Madrid
        • Contact:
          • Principal Investigator
      • Málaga, Espagne, 29010
        • Recrutement
        • Hospital Regional Universitario de Malaga
        • Contact:
          • Principal Investigator
      • Seville, Espagne, 41009
        • Recrutement
        • Hospital Universitario Virgen Macarena
        • Contact:
          • Principal Investigator
      • Seville, Espagne, 41013
        • Recrutement
        • Hospital Universitario Virgen Del Rocio
        • Contact:
          • Principal Investigator
      • Vigo, Espagne, 36312
        • Recrutement
        • Hospital Alvaro Cunqueiro
        • Contact:
          • Principal Investigator
      • Lille, France, 59037
        • Recrutement
        • Hopital Albert Calmette - Chu Lille
        • Contact:
          • Principal Investigator
      • Lyon, France, 69008
        • Recrutement
        • Centre Léon Bérard
        • Contact:
          • Principal Investigator
      • Marseille, France, 13005
        • Recrutement
        • Hôpital de la Timone
        • Contact:
          • Principal Investigator
      • Paris, France, 75005
        • Recrutement
        • Institut Curie - Site de Paris
        • Contact:
          • Principal Investigator
      • Paris, France, 75020
        • Recrutement
        • Hopital Tenon
        • Contact:
          • Principal Investigator
      • Rennes, France, 35000
        • Recrutement
        • Chu Rennes - Hopital Pontchaillou
        • Contact:
          • Principal Investigator
      • Saint-Herblain, France, 44805
        • Recrutement
        • CHU Nantes - Hôpital Guillaume et René Laënnec
        • Contact:
          • Principal Investigator
      • Suresnes, France, 92151
        • Recrutement
        • Hôpital Foch
        • Contact:
          • Principal Investigator
      • Villejuif, France, 94805
        • Pas encore de recrutement
        • Institut Gustave Roussy
        • Contact:
          • Principal Investigator
      • Himeji-shi, Japon, 670-8520
        • Recrutement
        • NHO Himeji Medical Center
      • Hirakata-shi, Japon, 573-1191
        • Recrutement
        • Kansai Medical University Hospital
        • Contact:
          • Principal Investigator
      • Kashiwa, Japon, 277-8577
        • Recrutement
        • National Cancer Center Hospital East
        • Contact:
          • Principal Investigator
      • Kumamoto, Japon, 861-4193
        • Recrutement
        • Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital
        • Contact:
          • Principal Investigator
      • Kōtoku, Japon, 135-8550
        • Recrutement
        • The Cancer Institute Hospital of Jfcr
        • Contact:
          • Principal Investigator
      • Nagaizumi-cho, Japon, 411-8777
        • Recrutement
        • Shizuoka Cancer Center
        • Contact:
          • Principal Investigator
      • Niigata, Japon, 951-8566
        • Recrutement
        • Niigata Cancer Center Hospital
        • Contact:
          • Principal Investigator
      • Okayama, Japon, 700-8558
        • Recrutement
        • Okayama University Hospital
        • Contact:
          • Principal Investigator
      • Tokushima, Japon, 770-8503
        • Recrutement
        • Tokushima University Hospital
      • Toyoake-shi, Japon, 470-1192
        • Recrutement
        • Fujita Health University Hospital
      • Ōsaka-sayama, Japon, 589-8511
        • Recrutement
        • Kindai University Hospital
        • Contact:
          • Principal Investigator
    • Alabama
      • Birmingham, Alabama, États-Unis, 35233
        • Recrutement
        • University of Alabama -Birmingham
        • Contact:
          • Principal Investigator
    • Arizona
      • Phoenix, Arizona, États-Unis, 85054
        • Recrutement
        • Mayo Clinic Arizona
        • Contact:
          • Principal Investigator
    • California
      • Los Angeles, California, États-Unis, 90095
        • Pas encore de recrutement
        • David Geffen School of Medicine
        • Contact:
          • Principal Investigator
      • Newport Beach, California, États-Unis, 92663
        • Recrutement
        • Hoag Memorial Hospital Presbyterian
        • Contact:
          • Principal Investigator
    • Florida
      • Jacksonville, Florida, États-Unis, 32224
        • Recrutement
        • Mayo Clinic-Jacksonville
        • Contact:
          • Principal Investigator
      • Orlando, Florida, États-Unis, 32804
        • Recrutement
        • Advent Health Orlando
        • Contact:
          • Principal Investigator
      • Tampa, Florida, États-Unis, 33612
        • Recrutement
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, États-Unis, 60611
        • Recrutement
        • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
        • Contact:
          • Principal Investigator
    • Michigan
      • Detroit, Michigan, États-Unis, 48202
        • Actif, ne recrute pas
        • Henry Ford Hospital
    • Minnesota
      • Minneapolis, Minnesota, États-Unis, 55455
        • Recrutement
        • Regents of the University of Minnesota
        • Contact:
          • Principal Investigator
      • Rochester, Minnesota, États-Unis, 55905
        • Recrutement
        • Mayo Clinic
        • Contact:
          • Principal Investigator
    • New Hampshire
      • Lebanon, New Hampshire, États-Unis, 03766
        • Recrutement
        • Dartmouth-Hitchcock Medical Center
        • Contact:
          • Principal Investigator
    • New Jersey
      • East Brunswick, New Jersey, États-Unis, 08816
        • Recrutement
        • Astera Cancer Care
      • Hackensack, New Jersey, États-Unis, 07601
        • Recrutement
        • John Theurer Cancer Center At Hackensack Umc
        • Contact:
          • Principal Investigator
    • New York
      • Mineola, New York, États-Unis, 11501
        • Recrutement
        • NYU Langone Hospital - Long Island
        • Contact:
          • Principal Investigator
      • Mineola, New York, États-Unis, 11501
        • Recrutement
        • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone
        • Contact:
          • Principal Investigator
      • New York, New York, États-Unis, 10021
        • Recrutement
        • Memorial Sloan Kettering Cancer Center
        • Contact:
          • Principal Investigator
      • New York, New York, États-Unis, 10461
        • Recrutement
        • Montefiore Medical Center
      • New York, New York, États-Unis, 10032
        • Recrutement
        • Columbia University Hervert Irving Comprehensive Cancer Center
        • Contact:
          • Principal Investigator
    • Pennsylvania
      • Lancaster, Pennsylvania, États-Unis, 17601
        • Recrutement
        • Lancaster General Hospital - Ann B Barshinger Cancer Institute
      • Philadelphia, Pennsylvania, États-Unis, 19104
        • Recrutement
        • University of Pennsylvania, Abramson Cancer Center
      • Philadelphia, Pennsylvania, États-Unis, 19107
        • Recrutement
        • Thomas Jefferson University Hospital - Central
        • Contact:
          • Principal Investigator
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37203
        • Recrutement
        • Scri Oncology Partners
        • Contact:
          • Principal Investigator
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Recrutement
        • Next Virginia
        • Contact:
          • Principal Investigator
    • Washington
      • Vancouver, Washington, États-Unis, 98684
        • Recrutement
        • Northwest Cancer Specialists, P.C.-Vancouver
        • Contact:
          • Principal Investigator
    • Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Recrutement
        • Medical College of Wisconsin
        • Contact:
          • Principal Investigator

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

A full list of inclusion/exclusion criteria are available in the protocol.

Inclusion Criteria

Participants must meet all of the following criteria to be eligible for enrollment into the study:

  1. Sign and date the informed consent form (ICF), prior to the start of any study-specific qualification procedures.

  2. Adults ≥18 years or the minimum legal adult age (whichever is greater) at the time the ICF is signed.

  3. Has histologically or cytologically confirmed diagnosis of ES-SCLC who will require first-line (IL) therapy.

  4. For Cohort 1, participant has received 4 cycles of 1L induction therapy with carboplatin, etoposide, and atezolizumab for ES-SCLC with ongoing CR PR, CR, or SD per RECIST v1.1 assessed by the investigator.

    For Cohort 2, participant has received no prior treatment for ES-SCLC.

  5. For Cohort 2, participant has at least one measurable lesion according to RECIST v1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by the investigator.

  6. For Cohort 2, participant must have at least one lesion, amenable to core biopsy, and must consent to provide a pretreatment biopsy tissue sample and on-treatment biopsy.

  7. Has ECOG PS of ≤1 (assessed within 7 days before enrollment/randomization).

  8. Has adequate organ and bone marrow function within 7 days before the start of study treatment as specified in the study protocol.

  9. A female subject of childbearing potential (POCBP) is eligible to participate if the following conditions are met:

    1. Subject is not pregnant as confirmed by highly sensitive pregnancy test during Screening (within 3 days prior to enrollment/randomization)
    2. Subject does not breastfeed during the treatment period and for at least 8/5/6 months after last dose of I-DXd/atezolizumab/carboplatin, respectively.
    3. Subject agrees to adhere to a contraceptive method that is highly effective and agrees not to donate eggs (ova, oocytes) to others or freeze/store eggs during the treatment period and for at least the time needed to eliminate each study drug after the last dose. The length of time required to continue contraception and avoid donating/freezing eggs after last dose for I-DXd/atezolizumab/carboplatin is 8/5/6 months, respectively. Preservation of eggs may be considered prior to first dose of study drug.
  10. A male subject capable of producing sperm is eligible to participate if he agrees to the following during the intervention period and for at least the time needed to eliminate each study drug. The length of time required to continue contraception and avoid donating sperm after last dose for I-DXd/atezolizumab/carboplatin is 6/5/6 months, respectively.

    1. Avoid donating sperm.
    2. Adhere to either of the contraception methods: true abstinence from penile-vaginal intercourse or uses a penile/external condom when having penile-vaginal intercourse with a non-subject of childbearing potential plus partner use of an additional contraceptive method.
  11. Is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions.

Exclusion Criteria

Participants who meet any of the following criteria will be disqualified from entering the study:

  1. Has received prior treatment with orlotamab, enoblituzumab, or other B7-H3 targeted agents, including I-DXd.
  2. Prior discontinuation of an ADC that consists of an exatecan derivative (eg, trastuzumab deruxtecan) due to treatment-related toxicities.
  3. Has received prior treatment with CD137 agonists or ICIs, including anti-cytotoxic T-cell lymphocyte-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, except for atezolizumab for Cohort 1.
  4. Has inadequate washout period before enrollment/randomization as specified in the study protocol.
  5. Has any of the following within the past 6 months: cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event.
  6. Has clinically active brain metastases, spinal cord compression, or leptomeningeal carcinomatosis, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms.
  7. Has clinically significant corneal disease.
  8. Has uncontrolled or significant cardiovascular disease,.
  9. Has history of (non-infectious) ILD/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at Screening.
  10. Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses
  11. Is on chronic steroid treatment (dose of 10 mg daily or more prednisone equivalent), except for low-dose inhaled steroids (for asthma/chronic obstructive pulmonary disease, topical steroids (for mild skin conditions), or intra-articular steroid injections.
  12. Has history of malignancy other than SCLC within the 5 years prior to randomization/enrollment, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial gastrointestinal tract tumors, and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
  13. Has history of allogeneic bone marrow, stem cell, or solid organ transplant.
  14. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE V5.0, Grade ≤1 or baseline.
  15. Has history of hypersensitivity to the drug substances, inactive ingredients in the drug product or severe hypersensitivity reactions to other monoclonal antibodies.
  16. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection.
  17. Has active or uncontrolled human immunodeficiency virus (HIV) infection.
  18. Has active or uncontrolled hepatitis B or C virus (HBV or HCV) infection.
  19. Has history of autoimmune disease.
  20. Has any evidence of severe or uncontrolled systemic diseases.
  21. Has received a live vaccine within 30 days prior to the first dose of study drug.
  22. Is a female who is pregnant or breastfeeding or planning to become pregnant.
  23. Has prior or ongoing clinically relevant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the investigator's opinion, could affect the safety of the participant; alter the absorption, distribution, metabolism, or excretion of the study drug; or confound the assessment of study results.
  24. Has psychological, social, familial, or logistical factors that would prevent regular follow-up

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Cohort 1, Part A: Maintenance Only (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

A 5-day surveillance period between each of the first 3 participants (up to a maximum of 9 participants) dosed is included as a safety measure.

Intravenous administration

Autres noms:
  • I-DXd

Intravenous administration

Expérimental: Cohort 2, Part A: Induction + Maintenance (I-DXd 8 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Autres noms:
  • I-DXd

Intravenous administration

Intravenous administration

Expérimental: Cohort 2, Part A: Induction + Maintenance (I-DXd 12 mg/kg)

Part A (Safety Run-in): Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Autres noms:
  • I-DXd

Intravenous administration

Intravenous administration

Expérimental: Cohort 1, Part B: Maintenance (I-DXd 8 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W

Intravenous administration

Autres noms:
  • I-DXd

Intravenous administration

Expérimental: Cohort 1, Part B: Maintenance (I-DXd 12 mg/kg)

Part B: Participants who must have received 4 cycles of 1L induction standard of care (SoC) therapy with best overall response of CR, PR, or SD will receive maintenance therapy only starting at Cycle 1 Day 1. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Autres noms:
  • I-DXd

Intravenous administration

Expérimental: Cohort 2, Part B: Induction + Maintenance (I-DXd 8 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of 1L I-DXd induction therapy (8 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×min IV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 8 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Autres noms:
  • I-DXd

Intravenous administration

Intravenous administration

Expérimental: Cohort 2, Part B: Induction + Maintenance (I-DXd 12 mg/kg)

Participants who are treatment-naive, newly diagnosed with ES-SCLC will receive 4 cycles of IL I-DXd induction therapy (12 mg/kg IV Q3W) + atezolizumab (1200 mg IV Q3W) + carboplatin (AUC 5 mg/ml×minIV Q3W) followed by maintenance therapy. Maintenance therapy consisting of I-DXd 12 mg/kg (or a lower dose based on data for I-DXd collected during the study) + atezolizumab 1200 mg IV Q3W.

Intravenous administration

Autres noms:
  • I-DXd

Intravenous administration

Intravenous administration

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Nombre de participants signalant des toxicités limitant la dose après l'I-DXd en association avec l'atezolizumab avec ou sans carboplatine (partie A)
Délai: Cycle 1 Jour 1 jusqu'au Cycle 1 Jour 21 (chaque cycle dure 21 jours)
Cycle 1 Jour 1 jusqu'au Cycle 1 Jour 21 (chaque cycle dure 21 jours)
Nombre total de participants présentant des événements indésirables survenus pendant le traitement après I-DXd en association avec l'atezolizumab avec ou sans carboplatine (parties A et B)
Délai: Base de référence jusqu'à 37 mois
Base de référence jusqu'à 37 mois

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression-free Survival As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
Délai: From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months

Progression-free survival is defined as the time from the enrollment/randomization date to the earlier of the dates of the first documentation of disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause.

From start date of study drug to the earlier date of the first objective documentation of radiographic disease progression assessed by BICR and investigator per RECIST v1.1 or death due to any cause, whichever occurs first, up to approximately 37 months
Objective Response Rate Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Délai: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Objective response rate (ORR) is defined as proportion of subjects who achieved a best overall response of confirmed complete response (CR) or confirmed partial response (PR) per BICR and investigator according to RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Duration of Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Délai: From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months

Duration of response (DoR) is defined as the time from the date of the first documentation of objective response (confirmed complete response [CR] or confirmed partial response [PR]) to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. The DoR will be calculated for responding participants (confirmed PR or confirmed CR) only.

From the date of first documentation of confirmed response (CR or PR) to the first documentation of objective progression or to death due to any cause, whichever occurs first, up to approximately 37 months
Disease Control Rate As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Délai: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Disease control rate is defined as the proportion of participants who have achieved a best overall response of confirmed CR, confirmed PR, or SD by BICR and investigator assessment per RECIST v1.1.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Clinical Benefit Rate as Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Délai: Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months

Clinical benefit rate (CBR) is defined as the proportion of participants who achieved a best overall response of confirmed CR, confirmed PR, or SD lasting for at least 180 days.

Baseline up until documented progressive disease, death, lost to follow-up, or withdrawal by the participant, up to approximately 37 months
Time to Response As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Délai: From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months

Time to response (TTR) is defined as the time from the date of enrollment/randomization to the date of the first documentation of objective response (confirmed CR or confirmed PR) in responding subjects.

From the start date of study drug to the date of the first documentation of response (CR or PR) that is subsequently confirmed, up to approximately 37 months
Best Percentage Change in the Sum of Diameters (SoD) of Measurable Tumors As Assessed by Blinded Independent Central Review and Investigator Following I-DXd in Combination With Atezolizumab With Carboplatin (Part A and B of Cohort 2 Only)
Délai: Baseline up to approximately 37 months

The best percentage change in SoD is defined as the percentage change in the smallest SoD from all post-baseline tumor assessments, taking as reference the baseline SoD.

Baseline up to approximately 37 months
Overall Survival Following I-DXd in Combination With Atezolizumab With or Without Carboplatin (Part A and B)
Délai: From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months

Time from the date of enrollment/randomization to the date of death due to any cause.

From the start date of study drug to the date of death due to any cause, whichever occurs first, up to approximately 37 months
Pharmacokinetic Parameter Maximum Serum Concentration of I-DXd
Délai: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Maximum serum concentration (Cmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Time to Maximum Serum Concentration of I-DXd
Délai: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Time to maximum serum concentration (Tmax) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
Pharmacokinetic Parameter Area Under the Concentration Curve of I-DXd
Délai: Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)

Area under the concentration-time curve up to the last quantifiable time (AUClast) and Area under the concentration-time curve during dosing interval (AUCtau) will be assessed using non-compartmental methods.

Cycle 1 Day 1 pre-dose up to Cycle 9 (and every 2 cycles thereafter up to 37 months) Day 1 pre-dose (each cycle is 21 days)
The Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive At Any Time and Who Have A Treatment-emergent Anti-Drug Antibody
Délai: Baseline up to approximately 37 months

The ADA prevalence, which is the percentage of participants who are ADA positive at any time point (baseline or postbaseline), as well as the ADA incidence, which is the proportion of participants having treatment-emergent ADA during the study period, will be reported.

Baseline up to approximately 37 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Directeur d'études: Global Clinical Leader, Daiichi Sankyo

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

22 juillet 2024

Achèvement primaire (Estimé)

20 juillet 2027

Achèvement de l'étude (Estimé)

20 février 2028

Dates d'inscription aux études

Première soumission

2 janvier 2024

Première soumission répondant aux critères de contrôle qualité

8 avril 2024

Première publication (Réel)

12 avril 2024

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

1 octobre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

28 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • DS7300-189
  • 2023-509629-36 (Autre identifiant: EU CT)
  • 2031240089 (Autre identifiant: JRCT)
  • 2023 (Subvention/contrat des NIH des États-Unis)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Délai de partage IPD

Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Critères d'accès au partage IPD

Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner